Cite
Dulla K, Slijkerman R, van Diepen HC, et al. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021;29(8):2441-2455doi: 10.1016/j.ymthe.2021.04.024.
Dulla, K., Slijkerman, R., van Diepen, H. C., Albert, S., Dona, M., Beumer, W., Turunen, J. J., Chan, H. L., Schulkens, I. A., Vorthoren, L., den Besten, C., Buil, L., Schmidt, I., Miao, J., Venselaar, H., Zang, J., Neuhauss, S. C. F., Peters, T., Broekman, S., Pennings, R., Kremer, H., Platenburg, G., Adamson, P., de Vrieze, E., & van Wijk, E. (2021). Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Molecular therapy : the journal of the American Society of Gene Therapy, 29(8), 2441-2455. https://doi.org/10.1016/j.ymthe.2021.04.024
Dulla, Kalyan, et al. "Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations." Molecular therapy : the journal of the American Society of Gene Therapy vol. 29,8 (2021): 2441-2455. doi: https://doi.org/10.1016/j.ymthe.2021.04.024
Dulla K, Slijkerman R, van Diepen HC, Albert S, Dona M, Beumer W, Turunen JJ, Chan HL, Schulkens IA, Vorthoren L, den Besten C, Buil L, Schmidt I, Miao J, Venselaar H, Zang J, Neuhauss SCF, Peters T, Broekman S, Pennings R, Kremer H, Platenburg G, Adamson P, de Vrieze E, van Wijk E. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021 Aug 04;29(8):2441-2455. doi: 10.1016/j.ymthe.2021.04.024. Epub 2021 Apr 23. PMID: 33895329; PMCID: PMC8353187.
Copy
Download .nbib